The peroxisome proliferator-activated receptors (PPAR alpha, gamma, delta)
are members of the nuclear receptor superfamily of ligand-activated transcr
iption factors that have central roles in the storage and catabolism of fat
ty acids. Although the three PPAR subtypes are closely related and bind to
similar DNA response elements as heterodimers with the 9-cis retinoic acid
receptor RXR, each subserves a distinct physiology. PPAR alpha (NR1CI) is t
he receptor for the fibrate drugs, which are widely used to lower triglycer
ides and raise high-density lipoprotein cholesterol levels in the treatment
and prevention of coronary artery disease. In rodents, PPAR alpha agonists
induce hepatomegaly and stimulate a dramatic proliferation of peroxisomes
as part of a coordinated physiological response to lipid overload. PPAR gam
ma (NRIC3) plays a critical role in adipocyte differentiation and serves as
the receptor for the glitazone class of insulin-sensitizing drugs used in
the treatment of type 2 diabetes. In contrast to PPAR alpha and PPAR gamma,
relatively little is known about the biology of PPARG (NRIC2), although re
cent findings suggest that this subtype also has a role in lipid homeostasi
s. All three PPARs are activated by naturally occurring fatty acids and fat
ty acid metabolites, indicating that they function as the body's fatty acid
sensors. Three-dimensional crystal structures reveal that the ligand-bindi
ng pockets of the PPARs are much larger and more accessible than those of o
ther nuclear receptors, providing a molecular basis for the promiscuous lig
and-binding properties of these receptors. Given the fundamental roles that
the PPARs play in energy balance, drugs that modulate PPAR activity are li
kely to be useful for treating a wide range of metabolic disorders, includi
ng atherosclerosis, dyslipidemia, obesity, and type 2 diabetes.